Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARGSQ OTCMKTS:BCTXF OTCMKTS:GLGLF OTCMKTS:OMGAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/ABCTXFBriaCell Therapeutics$0.70+6.6%$1.62$3.25▼$17.50$539K1.091,859 shs808,277 shsGLGLFGLG Life Tech$0.01$0.01▼$1.12$430K1.91N/AN/AOMGAQOmega Therapeutics$0.00$0.06$0.00▼$1.69$166K0.57215,590 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%BCTXFBriaCell Therapeutics0.00%-5.69%-12.70%-77.27%-19.31%GLGLFGLG Life Tech0.00%0.00%0.00%0.00%0.00%OMGAQOmega Therapeutics0.00%0.00%-84.21%-97.60%-99.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARGSQArgos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCTXFBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLGLFGLG Life TechN/AN/AN/AN/AN/AN/AN/AN/AOMGAQOmega Therapeutics2.4636 of 5 stars3.34.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARGSQArgos Therapeutics 0.00N/AN/AN/ABCTXFBriaCell Therapeutics 0.00N/AN/AN/AGLGLFGLG Life Tech 0.00N/AN/AN/AOMGAQOmega Therapeutics 2.50Moderate Buy$4.00133,233.33% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARGSQArgos Therapeutics$1.90M0.30N/AN/A($1.63) per share-0.03BCTXFBriaCell TherapeuticsN/AN/AN/AN/A($4.55) per shareN/AGLGLFGLG Life Tech$10.62M0.00N/AN/A($2.00) per share0.00OMGAQOmega Therapeutics$3.09M0.05N/AN/A$1.05 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARGSQArgos Therapeutics-$40.57MN/A0.00∞N/AN/AN/AN/AN/ABCTXFBriaCell Therapeutics-$3.68M-$3.84N/A∞N/AN/AN/A-786.77%N/AGLGLFGLG Life Tech$48.29M$1.320.00N/AN/A498.04%N/A-76.15%N/AOMGAQOmega Therapeutics-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/ALatest OMGAQ, ARGSQ, BCTXF, and GLGLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025GLGLFGLG Life TechN/A-$0.06N/A-$0.05N/A$2.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARGSQArgos TherapeuticsN/AN/AN/AN/AN/ABCTXFBriaCell TherapeuticsN/AN/AN/AN/AN/AGLGLFGLG Life TechN/AN/AN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARGSQArgos TherapeuticsN/AN/AN/ABCTXFBriaCell TherapeuticsN/A0.070.07GLGLFGLG Life TechN/A0.210.19OMGAQOmega TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARGSQArgos TherapeuticsN/ABCTXFBriaCell TherapeuticsN/AGLGLFGLG Life TechN/AOMGAQOmega Therapeutics97.47%Insider OwnershipCompanyInsider OwnershipARGSQArgos Therapeutics28.21%BCTXFBriaCell TherapeuticsN/AGLGLFGLG Life TechN/AOMGAQOmega Therapeutics8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARGSQArgos Therapeutics12210.59 millionN/ANot OptionableBCTXFBriaCell Therapeutics8772,000N/ANot OptionableGLGLFGLG Life Tech1238.39 millionN/ANot OptionableOMGAQOmega Therapeutics12055.37 million50.66 millionOptionableOMGAQ, ARGSQ, BCTXF, and GLGLF HeadlinesRecent News About These CompaniesOMGAQ - Omega Therapeutics Inc Executives | MorningstarAugust 5, 2025 | morningstar.comMOmega Therapeutics Inc (OMGAQ)March 5, 2025 | investing.comHuge distressed drugmaker seeks sale in Chapter 11 bankruptcyFebruary 27, 2025 | msn.comIntrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & ImmunologyFebruary 19, 2025 | markets.businessinsider.comOmega Therapeutics secures $9.8M in DIP financingFebruary 14, 2025 | msn.comOmega Therapeutics Hits Chapter 11February 10, 2025 | usaherald.comUFlagship’s Omega Thera to file for bankruptcyFebruary 5, 2025 | thepharmaletter.comTFlagship-backed Omega signals it’s headed toward bankruptcyFebruary 5, 2025 | biopharmadive.comBThe OMGA Conundrum: Why Omega Therapeutics Inc’s Stock Is Making Headlines AgainFebruary 5, 2025 | bovnews.comBNovo Partner Omega Waves Bankruptcy Flag from Sinking ShipFebruary 4, 2025 | biospace.comBFlagship spinout Omega is days away from bankruptcy, it says in filingFebruary 4, 2025 | endpts.comEWhat’s Behind the 11.36% Gain in Omega Therapeutics Inc (OMGA) Stock? Find Out Now!January 30, 2025 | bovnews.comBOmega Therapeutics announces board reshuffle and new directorJanuary 29, 2025 | msn.comFlagship Pioneering partners with Cambridge, UK institutionsJanuary 25, 2025 | thepharmaletter.comTOmega Therapeutics stock hits 52-week low at $0.52January 21, 2025 | msn.comOmega Therapeutics Appoints New Director Ravi MehrotraDecember 6, 2024 | tipranks.comOmega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams PropertyDecember 4, 2024 | accesswire.comAOmega Pacific Announces 2024 Work Program Results From Its Lekcin PropertyNovember 19, 2024 | accesswire.comAOmega Therapeutics Reports Third Quarter 2024 ResultsNovember 19, 2024 | markets.businessinsider.comOmega Therapeutics price target lowered to $4 from $9 at Piper SandlerNovember 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOMGAQ, ARGSQ, BCTXF, and GLGLF Company DescriptionsArgos Therapeutics OTCMKTS:ARGSQ$0.05 0.00 (0.00%) As of 10/10/2019Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.BriaCell Therapeutics OTCMKTS:BCTXF$0.70 +0.04 (+6.57%) As of 08/22/2025BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.GLG Life Tech OTCMKTS:GLGLFGLG Life Tech Corporation researches for, develops, grows, refines, and produces natural sweeteners extracted from the stevia plant and monk fruit in Canada and internationally. It also offers P-Pro Plus, a pea protein product; REB M GOLD, a bioconverted Rebaudioside M and Rebaudioside D. sweetener; and natural ingredients. It serves in the food and beverage industry. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.Omega Therapeutics OTCMKTS:OMGAQ$0.0030 0.00 (0.00%) As of 08/11/2025Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buffett’s Wisdom Could Spell Trouble for Palantir Shorts Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Reynolds Consumer Products Stock Price: Insiders Signal a Bottom Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a Trend How a Superstore Strategy Fueled MINISO’s 20% Stock Surge Petrobras: Why Traders Are Betting Big on a Shareholder Payout Southern Company: From Nuclear Risk to AI Reward BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access